- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Wrapping up the month of August, Gabrielle and Charlotte share with investors some of the biggest highlights from the month, including news about clinical trials, the US Food and Drug Administration and major lawsuits.
With August behind us, the Investing News Network (INN) takes a look back at what some of the biggest highlights were in the various life science sectors, including clinical trials, US Food and Drug Administration (FDA) updates and lawsuits.
Bellerophon Therapeutics (NASDAQ:BLPH) announced in early August that its Phase 3 clinical trial for INOvation would be stopped due to futility. This was after an unsuccessful interim analysis from the Data Monitoring Committee (DMC), which found the primary endpoint was insufficient to support the continuation fo the study.
However, this may not be the end for Bellerophon’s program as the company was impressed by positive data in hemodynamics and the safety and tolerability profile of INOpulse. The company will continue to review the full data set from this trial.
In terms of FDA news, the agency approved the expansion of AVITA Medical’s (OTCQX:AVMXY; ASX:AVH) clinical trial for the Recell Autologous Cell Harvesting Device. The expansion will allow a significant increase in testing, which will include more patients and US burn centers for the trial.
The device has the potential to allow medical professionals to use a patient’s cell samples to create a suspension and use it to regenerate wounded skin. The company believes the device could replace the current standard of treatment from skin grafting technology.
Lastly, Bayer (OTCPINK:BAYRY, ETR:BAYN) was ordered to pay a US$289 million settlement in mid-August over Monsanto’s Roundup product, which allegedly linked the company’s pesticide and cancer. Bayer’s share price dipped 17 percent as a result of the announcement.
For more on what happened during the month of August for the life science sectors, watch the video above.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â